Czech National Bank Has $154.06 Million Stock Position in Eli Lilly and Company $LLY

Czech National Bank boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 5.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 201,919 shares of the company’s stock after acquiring an additional 9,641 shares during the quarter. Eli Lilly and Company makes up approximately 1.1% of Czech National Bank’s holdings, making the stock its 12th biggest holding. Czech National Bank’s holdings in Eli Lilly and Company were worth $154,064,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in shares of Eli Lilly and Company by 1.5% in the second quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock valued at $62,680,004,000 after purchasing an additional 1,183,038 shares in the last quarter. Laurel Wealth Advisors LLC boosted its position in Eli Lilly and Company by 78,621.2% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after buying an additional 11,537,661 shares during the last quarter. Norges Bank acquired a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at $8,827,714,000. Jennison Associates LLC raised its position in shares of Eli Lilly and Company by 4.3% during the second quarter. Jennison Associates LLC now owns 5,447,636 shares of the company’s stock worth $4,246,596,000 after acquiring an additional 226,620 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its stake in shares of Eli Lilly and Company by 7.9% during the first quarter. Alliancebernstein L.P. now owns 5,443,919 shares of the company’s stock valued at $4,496,187,000 after acquiring an additional 397,696 shares during the period. 82.53% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Scotiabank began coverage on Eli Lilly and Company in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $1,165.00 price objective for the company. BMO Capital Markets set a $1,200.00 price target on shares of Eli Lilly and Company in a research report on Thursday, December 4th. Daiwa Capital Markets set a $1,230.00 price target on shares of Eli Lilly and Company and gave the stock a “buy” rating in a research note on Tuesday. CICC Research increased their price objective on shares of Eli Lilly and Company from $801.00 to $1,060.00 and gave the company a “neutral” rating in a report on Thursday, November 13th. Finally, Truist Financial raised their price objective on shares of Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the company a “buy” rating in a research note on Wednesday, November 19th. Four research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $1,141.73.

Eli Lilly and Company Stock Up 1.4%

Eli Lilly and Company stock opened at $1,056.57 on Friday. The firm has a market capitalization of $998.86 billion, a price-to-earnings ratio of 51.69, a PEG ratio of 1.31 and a beta of 0.37. The company’s 50 day simple moving average is $956.00 and its 200 day simple moving average is $828.10. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,111.99.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business’s revenue for the quarter was up 53.9% compared to the same quarter last year. During the same period last year, the business posted $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a yield of 0.7%. The ex-dividend date is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.